时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
摘要（PubMed 原文节选）
Precision nutritional interventions targeting the gut microenvironment have emerged as a pivotal strategy for managing inflammatory bowel disease (IBD). However, the specific microbial mechanisms governing the therapeutic efficacy of dietary flavonoids, such as daidzein (DA), remain largely unexplored. In this study, it was observed that …
对本项目的价值
参考价值：属「干细胞 / 部分重编程与再生」方向；干细胞 / 再生 / 重编程栏目可用作本项目文献库与综述素材。 ｜ 价值分 1.8/5（★★☆☆☆）
全文不可及原因
无 PMCID 且 Europe PMC / OpenAlex / Unpaywall 未提供可下载 OA 全文
原文题录
- 中文题名：肠道菌群来源 β-葡萄糖醛酸苷酶经 ERβ-PI3K/Akt/mTOR-自噬轴决定大豆苷元的抗结肠炎效力
- 英文标题：Gut Microbiota-Derived β-Glucuronidase Governs the Anticolitic Efficacy of Daidzein via the ERβ-PI3K/Akt/mTOR-Autophagy Axis.
- 期刊与标识：Journal of agricultural and food chemistry · PMID 42980395 · DOI 10.1021/acs.jafc.6c08490